Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering Sells 15,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 15,000 shares of the stock in a transaction on Monday, March 25th. The shares were sold at an average price of $66.93, for a total value of $1,003,950.00. Following the completion of the sale, the chief executive officer now owns 477,847 shares of the company’s stock, valued at approximately $31,982,299.71. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Grant Pickering also recently made the following trade(s):

• On Friday, March 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The stock was sold at an average price of $73.70, for a total transaction of $192,799.20.
• On Thursday, February 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The shares were sold at an average price of $73.91, for a total transaction of $193,348.56.
• On Monday, January 29th, Grant Pickering sold 30,000 shares of Vaxcyte stock. The stock was sold at an average price of $66.03, for a total value of $1,980,900.00.
• On Tuesday, January 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $63.92, for a total value of $958,800.00.
• On Tuesday, January 2nd, Grant Pickering sold 2,616 shares of Vaxcyte stock. The stock was sold at an average price of $63.89, for a total value of $167,136.24.

Vaxcyte Price Performance

Shares of NASDAQ:PCVX opened at $68.50 on Thursday. The company’s 50-day moving average price is $71.06 and its two-hundred day moving average price is $59.49. Vaxcyte, Inc. has a 12 month low of $34.11 and a 12 month high of $82.04.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same period last year, the company posted ($0.73) earnings per share. On average, sell-side analysts expect that Vaxcyte, Inc. will post -4.18 EPS for the current fiscal year.

Institutional Trading of Vaxcyte

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in Vaxcyte by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 8,452,371 shares of the company’s stock valued at $530,809,000 after acquiring an additional 168,125 shares during the period. RA Capital Management L.P. boosted its stake in shares of Vaxcyte by 8.2% during the 2nd quarter. RA Capital Management L.P. now owns 7,891,254 shares of the company’s stock worth $394,089,000 after buying an additional 600,000 shares during the last quarter. BlackRock Inc. grew its stake in Vaxcyte by 39.0% in the second quarter. BlackRock Inc. now owns 7,065,088 shares of the company’s stock valued at $352,830,000 after purchasing an additional 1,983,223 shares in the last quarter. Wellington Management Group LLP raised its position in Vaxcyte by 3.8% during the third quarter. Wellington Management Group LLP now owns 4,598,712 shares of the company’s stock worth $234,442,000 after acquiring an additional 167,501 shares in the last quarter. Finally, Capital Research Global Investors grew its position in shares of Vaxcyte by 2.3% in the 4th quarter. Capital Research Global Investors now owns 3,440,107 shares of the company’s stock valued at $216,039,000 after acquiring an additional 75,980 shares during the period. 96.78% of the stock is owned by institutional investors.

Analysts Set New Price Targets

PCVX has been the subject of a number of recent analyst reports. Bank of America upped their price target on shares of Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, January 2nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research report on Friday, January 12th. Needham & Company LLC increased their target price on shares of Vaxcyte from $73.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, February 28th. Finally, Mizuho began coverage on shares of Vaxcyte in a report on Thursday, December 7th. They set a “buy” rating and a $69.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $78.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.